222 related articles for article (PubMed ID: 29158470)
1. Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer.
Naik S; Galyon GD; Jenks NJ; Steele MB; Miller AC; Allstadt SD; Suksanpaisan L; Peng KW; Federspiel MJ; Russell SJ; LeBlanc AK
Mol Cancer Ther; 2018 Jan; 17(1):316-326. PubMed ID: 29158470
[TBL] [Abstract][Full Text] [Related]
2. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
LeBlanc AK; Naik S; Galyon GD; Jenks N; Steele M; Peng KW; Federspiel MJ; Donnell R; Russell SJ
Hum Gene Ther Clin Dev; 2013 Dec; 24(4):174-81. PubMed ID: 24219832
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
[TBL] [Abstract][Full Text] [Related]
4. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.
Zhang L; Steele MB; Jenks N; Grell J; Suksanpaisan L; Naik S; Federspiel MJ; Lacy MQ; Russell SJ; Peng KW
Hum Gene Ther Clin Dev; 2016 Sep; 27(3):111-22. PubMed ID: 27532609
[TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: A systematic review.
Moglan AM; Albaradie OA; Alsayegh FF; Alharbi HM; Samman YM; Jalal MM; Saeedi NH; Mahmoud AB; Alkayyal AA
Front Immunol; 2023; 14():1085940. PubMed ID: 37063914
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
7. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
8. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.
Cook J; Peng KW; Witzig TE; Broski SM; Villasboas JC; Paludo J; Patnaik M; Rajkumar V; Dispenzieri A; Leung N; Buadi F; Bennani N; Ansell SM; Zhang L; Packiriswamy N; Balakrishnan B; Brunton B; Giers M; Ginos B; Dueck AC; Geyer S; Gertz MA; Warsame R; Go RS; Hayman SR; Dingli D; Kumar S; Bergsagel L; Munoz JL; Gonsalves W; Kourelis T; Muchtar E; Kapoor P; Kyle RA; Lin Y; Siddiqui M; Fonder A; Hobbs M; Hwa L; Naik S; Russell SJ; Lacy MQ
Blood Adv; 2022 Jun; 6(11):3268-3279. PubMed ID: 35175355
[TBL] [Abstract][Full Text] [Related]
9. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
10. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma.
Makielski KM; Sarver AL; Henson MS; Stuebner KM; Borgatti A; Suksanpaisan L; Preusser C; Tabaran AF; Cornax I; O'Sullivan MG; Chehadeh A; Groschen D; Bergsrud K; Pracht S; Winter A; Mills LJ; Schwabenlander MD; Wolfe M; Farrar MA; Cutter GR; Koopmeiners JS; Russell SJ; Modiano JF; Naik S
Mol Ther Oncolytics; 2023 Dec; 31():100736. PubMed ID: 37965295
[TBL] [Abstract][Full Text] [Related]
13. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses.
Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A
Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674
[TBL] [Abstract][Full Text] [Related]
14. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
Betancourt D; Ramos JC; Barber GN
J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma.
Makielski KM; Sarver AL; Henson MS; Stuebner KM; Borgatti A; Suksanpaisan L; Preusser C; Tabaran AF; Cornax I; O'Sullivan MG; Chehadeh A; Groschen D; Bergsrud K; Pracht S; Winter A; Mills LJ; Schwabenlander MD; Wolfe M; Farrar MA; Cutter GR; Koopmeiners JS; Russell SJ; Modiano JF; Naik S
bioRxiv; 2023 Sep; ():. PubMed ID: 37131624
[TBL] [Abstract][Full Text] [Related]
16. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
[TBL] [Abstract][Full Text] [Related]
17. Blood Outgrowth Endothelial Cells as a Cellular Carrier for Oncolytic Vesicular Stomatitis Virus Expressing Interferon-β in Preclinical Models of Non-Small Cell Lung Cancer.
Patel MR; Jacobson BA; Ji Y; Hebbel RP; Kratzke RA
Transl Oncol; 2020 Jul; 13(7):100782. PubMed ID: 32422574
[TBL] [Abstract][Full Text] [Related]
18. Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy.
Cejalvo T; Perisé-Barrios AJ; Del Portillo I; Laborda E; Rodriguez-Milla MA; Cubillo I; Vázquez F; Sardón D; Ramirez M; Alemany R; Del Castillo N; García-Castro J
Cancer Res; 2018 Sep; 78(17):4891-4901. PubMed ID: 29991502
[TBL] [Abstract][Full Text] [Related]
19. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
[TBL] [Abstract][Full Text] [Related]
20. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.
Hastie E; Grdzelishvili VZ
J Gen Virol; 2012 Dec; 93(Pt 12):2529-2545. PubMed ID: 23052398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
